Our Platforms
Driving innovation with state-of-the-art platforms designed to unlock novel therapeutics and ensure targeted delivery.
Two Precision Nano Delivery Platforms
Tumor-targeting nanocarriers engineered for controlled, on-demand therapeutic delivery with enhanced efficacy and minimized toxicity.
Nano‑Carrier-based Peptide-Drug Conjugates (NC-PDC)
Modular precision nanomedicine systems integrating:
- • Targeting Peptide or Nanobody Ligands - bind tumor-specific antigens to guide the nanoparticle to target
- • Biocompatible Nanocarrier - protects drug, increases half-life over free drug
- • Covalently loaded payload - prevents premature release of cytotoxic drug
- • Tunable Linkers - controlled, environment-triggered drug release, tuned to tumor microenvironment (TME)
Engineered‑Carrier-based Nanobody-Drug Conjugates (EC-NDC)
Result = Potent, safer, versatile, targeted cancer therapy
How they work
The nanocarrier system combines:
- EPR* accumulation mechanisms
-
Build-in mechanisms:
- • Active transportation to TME*
- • Retention in tumor sites
- • Active targeting - ligands identify tumor cells
- → enhances accumulation and residence time in tumor tissues
- Covalent linker prevents premature payload release
- Tumor microenvironment triggers intracellular drug release
Why they will be superior to ADCs
Greater tumor but not organ exposure
Stable in blood; controlled drug release in tumor
Reduced systemic toxicity
High loading capacity for payloads
Multiple payloads
Scalable solid-phase and solution-phase synthesis
Ease of commercial manufacturing
Platform = multiple oncology indications
